Intravenous administration of the selective toll-like receptor 7 agonist DSR-29133 leads to anti-tumor efficacy in murine solid tumor models which can be potentiated by combination with fractionated radiotherapy

Strategies to augment anti-cancer immune responses have recently demonstrated therapeutic utility. To date clinical success has been achieved through targeting co-inhibitory checkpoints such as CTLA-4, PD-1, and PD-L1. However, approaches that target co-activatory pathways are also being actively be...

Descripción completa

Detalles Bibliográficos
Autores principales: Dovedi, Simon J., Adlard, Amy L., Ota, Yosuke, Murata, Masashi, Sugaru, Eiji, Koga-Yamakawa, Erina, Eguchi, Ken, Hirose, Yuko, Yamamoto, Setsuko, Umehara, Hiroki, Honeychurch, Jamie, Cheadle, Eleanor J., Hughes, Gareth, Jewsbury, Philip J., Wilkinson, Robert W., Stratford, Ian J., Illidge, Timothy M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4941369/
https://www.ncbi.nlm.nih.gov/pubmed/26959743
http://dx.doi.org/10.18632/oncotarget.7928

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4941369/
https://www.ncbi.nlm.nih.gov/pubmed/26959743
http://dx.doi.org/10.18632/oncotarget.7928

Ejemplares similares